Floatz logo

POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW)

Lung Diseases

Synspira, Inc.OtherPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Lung Diseases cohort.

Asset / SponsorPhaseRating
Carboplatin
Jiangmen Central Hospital
Phase 3BB
Ivacaftor
University of British Columbia
Phase 3BB
Theophylline
NCIC Clinical Trials Group
Phase 3BB
Lumacaftor
Vertex Pharmaceuticals Incorporated
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3B

View all 50 →

Same molecule, other indications

POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW) is also rated in:

pneumonitisDormant
CC
Indicative ·
43 / 100
View asset →
burkholderia infectious diseaseDormant
CC
Indicative ·
43 / 100
View asset →
respiratory system disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →